Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
Sharon B Wigal,1 Tim Wigal,1 Mary Hobart,2 Jessica J Madera,3 Ross A Baker,3 Eva Kohegyi,3 Anthony McKinney,4 Timothy E Wilens5 1AVIDA Inc., Newport Beach, California, USA; 2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA; 3Otsuka Pharmaceutical Developm...
Saved in:
Main Authors: | Wigal SB, Wigal T, Hobart M, Madera JJ, Baker RA, Kohegyi E, McKinney A, Wilens TE |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/3e6cabdeeaf74eb7b39e551e80cb4f1e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia
by: Xin KZ, et al.
Published: (2019) -
The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
by: McIntyre RS
Published: (2017) -
Serotonin Discharge Regulation by Additional Neurotransmitters of Rat Hippocampus Associated With the Continence Central Circuit
by: Jae Heon Kim, et al.
Published: (2021) -
Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder
by: Markowitz JT, et al.
Published: (2020) -
The noradrenergic paradox: implications in the management of depression and anxiety
by: Montoya A, et al.
Published: (2016)